Loading...
OTCM
BMXMF
Market cap11bUSD
Oct 15, Last price  
100.57
Name

Biomerieux SA

Chart & performance

D1W1MN
OTCM:BMXMF chart
P/E
—
P/S
—
EPS
3.36
Vol. 1Y
—
Shs. 5Y
0.06%
Rev. 5Y
5.47%
Div Yld LY
—
Div Yld TTM
—
Revenues
4.07b
+2.26%
1,036,900,0001,062,800,0001,110,500,0001,223,400,0001,357,000,0001,427,200,0001,569,800,0001,587,900,0001,698,400,0001,964,600,0002,103,200,0002,288,200,0002,421,300,0002,674,800,0003,118,200,0003,376,200,0003,589,100,0003,674,700,0003,979,900,0004,069,800,000
Net income
398m
-8.03%
105,300,00098,100,000130,000,000148,200,000160,000,000158,200,000134,400,000164,300,000134,900,000110,500,000179,100,000238,100,000256,600,000272,800,000404,400,000601,100,000452,400,000357,600,000432,200,000397,500,000
CFO
788m
+18.13%
124,600,000188,700,000197,900,000188,600,000199,000,000216,600,000258,500,000240,500,000298,300,000310,000,000335,600,000341,300,000399,800,000407,900,000582,800,000824,700,000475,100,000445,400,000667,300,000788,300,000
Dividend
Jun 09, 20261.13071 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.

Related entities

Subsidiaries (10)
BIOMERIEUX ASIA PACIFIC PTE. LTD.
bioMerieux Benelux
Biomerieux China Limited
BIOMERIEUX CZ S.R.O.
BIOMERIEUX ITALIA SPA
BIOMERIEUX MEXICO SA DE CV
bioMerieux Sweden AB
BIOMERIEUX, INC.
BTF PTY. LIMITED
BIOFIRE DIAGNOSTICS, LLC

Key people

Alexandre Merieux
Chairman of the Board · since 2023
Pierre Boulud
Chief Executive Officer, Member of the Executive Board · since 2023
Guillaume Bouhours
Chief Financial Officer, Executive Vice President - Purchasing and Information Systems, Member of the Executive Committee · since 2019
Pierre Charbonnier
Executive Vice President - Global Quality, Manufacturing and Supply Chain, Member of the Executive Committee
Audrey Dauvet
Executive Vice President - Legal Corporate Integrity and Public Affairs, General Counsel, Member of the Executive Committee · since 2024
Valerie Leylde
Executive Vice President - Human Resources, Communication and CSR, Member of the Executive Committee · since 2022
Charles Cooper
Executive Vice President, Chief Medical Officer, Member of the Executive Committee · since 2024
Yasha Mitrotti
Executive Vice President - Industrial Applications, Member of the Executive Committee · since 2024
Celine Roger-Dalbert
Executive Director - Research and Development, Member of the Executive Committee · since 2024
Jennifer Zinn
Executive Vice President - Clinical Operations, Member of the Executive Committee · since 2023
Philippe Archinard
Non-Independent Director · since 2010
Jean-Luc Belingard
Non-Independent Director · since 2017
Harold Boeel
Non-Independent Director · since 2024
Mariehelene Habert-Dassault
Non-Independent Director · since 2024
Sylvain Orenga
Director - Representing Employees · since 2022
Marie-Paule Kieny
Independent Director · since 2017
Fanny Letier
Independent Director · since 2017
Viviane Monges
Independent Director · since 2024
URL
https://www.biomerieux.com/fr/fr.html
IPO date
Jun 07, 2004
Employees
12,557
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
376 CHEMIN DE L'ORME
MARCY-L'ETOILE, 69 69280
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT